Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation

Transfusion

Volumn 53, Issue 6, 2013, Pages 1187-1200

  Hechler, Béatrice ^a   Ohlmann, Philippe ^a   Chafey, Philippe ^a   Ravanat, Catherine ^a   Eckly, Anita ^a   Maurer, Eric ^a   Mangin, Pierre ^a   Isola, Hervé ^a   Cazenave, Jean Pierre ^a   Gachet, Christian ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; CYTOPLASM PROTEIN; GLYCOPROTEIN IB ALPHA; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; INTEGRIN LINKED KINASE; LIPOCORTIN 5; PADGEM PROTEIN; PLECKSTRIN;

ARTICLE; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; GEL ELECTROPHORESIS; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MORPHOLOGY; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEOMICS; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; ULTRAVIOLET A RADIATION;

ANNEXIN A5; BLOOD BANKS; BLOOD BUFFY COAT; BLOOD PLATELETS; BLOOD PRESERVATION; BLOOD SAFETY; BLOOD-BORNE PATHOGENS; CRYOPRESERVATION; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; P-SELECTIN; PHOTOSENSITIZING AGENTS; PLATELET ADHESIVENESS; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; PROTEOMICS; PSORALENS; ULTRAVIOLET RAYS;

EID: 84878936568     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03923.x     Document Type: Article

References (47)

1. Corash L. Bacterial contamination of platelet components: potential solutions to prevent transfusion-related sepsis. Expert Rev Hematol 2011;4:509-25.
2. Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009;49(Suppl 2):1S-29S.
3. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007; 131:719-33.
4. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, Metzel P, Corash L. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
5. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, Metzel P, Corash L. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45: 580-90.
6. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood system. Transfu Med Hemother 2011;38: 19-31.
7. Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, Baril L, Davis K, Buchholz DH, Corash L, Conlan MG. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44: 1732-40.
8. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104:1534-41.
9. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, Conlan MG. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 2006;46:731-40.
10. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforet M, Raidot JP, Kandel G, Wiesel ML, Corash L. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51:622-9.
11. Osselaer JC, Cazenave JP, Lambermont M, Garraud O, Hidajat M, Barbolla L, Tardivel R, Defoin L, Waller C, Mendel I, Raidot JP, Kandel G, De Meuter R, Fabrigli P, Dehenau D, Arroyo JL, Padron F, Gouezec H, Corral M, Jacquet M, Sundin D, Lin L, Corash L. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008;94:315-23.
12. Osselaer JC, Messe N, Hervig T, Bueno J, Castro E, Espinosa A, Accorsi P, Junge K, Jacquet M, Flament J, Corash L. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008;48:1061-71.
13. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, Van Hooydonk M, Bosly A, Lin JS, Lin L, Corash L. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.
14. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45:1443-52.
15. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, Vermeij H, Kappers-Klunne M, de Greef G, Laforet M, Lioure B, Davis K, Marblie S, Mayaudon V, Flament J, Conlan M, Lin L, Metzel P, Buchholz D, Corash L. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
16. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010;150: 209-17.
17. Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, Roddie H, Pelly J, Docherty A, Sherman C, Lin L, Propst M, Corash L, Prowse C. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br J Haematol 2011;153: 393-401.
18. Apelseth TO, Bruserud O, Wentzel-Larsen T, Bakken AM, Bjorsvik S, Hervig T. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007;47:653-65.
19. Lin L, Cook DN, Wiesehahn GP, Alfonso R, Behrman B, Cimino GD, Corten L, Damonte PB, Dikeman R, Dupuis K, Fang YM, Hanson CV, Hearst JE, Lin CY, Londe HF, Metchette K, Nerio AT, Pu JT, Reames AA, Rheinschmidt M, Tessman J, Isaacs ST, Wollowitz S, Corash L. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
20. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang 2000;79:206-14.
21. Shrivastava M. The platelet storage lesion. Transfus Apher Sci 2009;41:105-13.
22. Cazenave JP, Ohlmann P, Cassel D, Eckly A, Hechler B, Gachet C. Preparation of washed platelet suspensions from human and rodent blood. Methods Mol Biol 2004; 272:13-28.
23. Kinlough-Rathbone RL, Mustard JF, Packham MA, Perry DW, Reimers HJ, Cazenave JP. Properties of washed human platelets. Thromb Haemost 1977;37:291-308.
24. Keuren JF, Cauwenberghs S, Heeremans J, de Kort W, Heemskerk JW, Curvers J. Platelet ADP response deteriorates in synthetic storage media. Transfusion 2006;46:204-12.
25. Baurand A, Eckly A, Bari N, Leon C, Hechler B, Cazenave JP, Gachet C. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemost 2000;84:484-91.
26. Kunicki TJ, Tuccelli M, Becker GA, Aster RH. A study of variables affecting the quality of platelets stored at "room temperature." Transfusion 1975;15:414-21.
27. Chafey P, Finzi L, Boisgard R, Cauzac M, Clary G, Broussard C, Pegorier JP, Guillonneau F, Mayeux P, Camoin L, Tavitian B, Colnot S, Perret C. Proteomic analysis of betacatenin activation in mouse liver by DIGE analysis identifies glucose metabolism as a new target of the Wnt pathway. Proteomics 2009;9:3889-900.
28. Jansen GA, van Vliet HH, Vermeij H, Beckers EA, Leebeek FW, Sonneveld P, van Rhenen DJ. Functional characteristics of photochemically treated platelets. Transfusion 2004; 44:313-9.
29. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogenreduction. Vox Sang 2009;97:26-33.
30. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen-HCl for pathogen inactivation. Transfusion 2004;44:320-9.
31. Janetzko K, Lin L, Eichler H, Mayaudon V, Flament J, Kluter H. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86:239-45.
32. Cognasse F, Osselaer JC, Payrat JM, Chavarin P, Corash L, Garraud O. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008;48:809-13.
33. Picker SM, Kaleta T, Hekmat K, Kampe S, Gathof BS. Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome. Eur J Anaesthesiol 2007;24:332-9.
34. Hitzler W, Vamvakas EC. Platelet microRNA profiles and the effect of pathogen reduction on platelet function. Clin Lab 2011;57:451-4.
35. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol 2009;16:961-6.
36. Egan K, FitzGerald GA. Eicosanoids and the vascular endothelium. Handb Exp Pharmacol 2006;(176 Pt 1) 189-211.
37. Marcus AJ, Broekman MJ, Drosopoulos JH, Olson KE, Islam N, Pinsky DJ, Levi R. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 2005;31:234-46.
38. Miyaji R, Sakai M, Urano H, Nakata K, Sakamoto H, Shirahata A. Decreased platelet aggregation of platelet concentrate during storage recovers in the body after transfusion. Transfusion 2004;44:891-9.
39. Rinder HM, Smith BR. In vitro evaluation of stored platelets: is there hope for predicting posttransfusion platelet survival and function? Transfusion 2003;43: 2-6.
40. Mondoro TH, Shafer BC, Vostal JG. Restoration of in vitro responses in platelets stored in plasma. Am J Clin Pathol 1999;111:693-9.
41. Lozano M, Galan A, Mazzara R, Corash L, Escolar G. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007;47:666-71.
42. Bruchmuller I, Losel R, Bugert P, Corash L, Lin L, Kluter H, Janetzko K. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets 2005;16:441-5.
43. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Annexin V release and transmembrane mitochondrial potential during storage of apheresis-derived platelets treated for pathogen reduction. Transfus Med Hemother 2010;37:7-12.
44. Knutson F, Alfonso R, Dupuis K, Mayaudon V, Lin L, Corash L, Hogman CF. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000;78:209-16.
45. Thiele T, Steil L, Volker U, Greinacher A. Transfusion medicine and proteomics. Alliance or coexistence? Blood Transfus 2010;8(Suppl 3):s16-25.
46. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
47. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010;362:600-13.